Michael J. Morris, MD, discusses the FDA approval of lutetium Lu 177 vipivotide tetraxetan plus an ARPI in PSMA+ mHSPC.
Related to this article
Leonard J. Appleman, MD, PhD, discusses prior data with SYNC-T Therapy SV-102 and the ongoing LEGION-100 study in prostate cancer.
The top 5 OncLive TV videos of the week cover insights in melanoma, prostate cancer, breast cancer, multiple myeloma, and small cell lung cancer.
lan M. Thompson Jr, MD, discusses the potential role of 5-ARIs for the treatment of patients with prostate cancer.
Adding an IL-15 receptor superagonist to a vaccine plus bintrafusp alfa produced clinical responses in pMMR CRPC.
The FDA has approved lutetium Lu 177 vipivotide tetraxetan plus an ARPI for PSMA-positive metastatic hormone-sensitive prostate cancer.
Advertisement
Advertisement
Trending on OncLive
1
Neoadjuvant Ivonescimab Plus Chemotherapy Yields pCRs in Resectable HNSCC
2
Pooled Analysis Reveals Strong Pirtobrutinib Efficacy in Frontline CLL
3
Researchers Discover Immune 'Off Switch' Used by Cancer Cells
4
Lutetium Lu 177 Vipivotide Tetraxetan Approval Reshapes the Treatment Landscape for PSMA+ mHSPC
5